Dear Shareholders and Investors,
2016 marked a trial year for us in terms of the clinical development project for micellar nanoparticle technology. We have faced on the difficulty of drug development, although we are fully aware that the results of preclinical trials, including animal testing, will not always be reflected in the clinical study results. This provided us with the opportunity to give a lot of thought to future improvements. It also became the reason why we have renewed our commitment to introduce new ideas, maintain our beliefs, pursue possibilities and continue to challenge ourselves so as to pave the way for success. Fortunately, we have a number of specialized employees who have worked for the first rated pharmaceutical companies and/or are experienced in pharmaceutical development. We also have pharmaceutical advisors in Japan and abroad. To materialize the pharmaceutical products based on micellar nanoparticle technology, we will fully devote ourselves to development strategy and promotion for approvals and also proceed with global development while identifying diseases that are highly likely to lead to approved indications.
As announced, we are constantly discussing the M&A strategy for new technology to expand our business as well as the arrangement of functions that we should have as a pharmaceutical company. In addition, we will enhance the cosmetics business and promote activities for further growth. Your continued support of our activities would be greatly appreciated.
Ichiro Nakatomi, PhD
President & CEO
January 1, 2017